Cargando…
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
BACKGROUND: We have previously reported that the safety and efficacy of ipilimumab in real-world patients with metastatic melanoma were comparable to clinical trials. Few studies have explored health-related quality of life (HRQL) in real-world populations receiving checkpoint inhibitors. This study...
Autores principales: | Aamdal, E., Skovlund, E., Jacobsen, K.D., Straume, O., Kersten, C., Herlofsen, O., Karlsen, J., Hussain, I., Amundsen, A., Dalhaug, A., Nyakas, M., Hagene, K.T., Holmsen, K., Aamdal, S., Kaasa, S., Guren, T.K., Kyte, J.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588897/ https://www.ncbi.nlm.nih.gov/pubmed/36116420 http://dx.doi.org/10.1016/j.esmoop.2022.100588 |
Ejemplares similares
-
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019) -
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
por: Aamdal, Elin, et al.
Publicado: (2021) -
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
por: Sioud, Mouldy, et al.
Publicado: (2016) -
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
por: Brunsvig, Paal F., et al.
Publicado: (2020) -
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)